Classic Familial Adenomatous Polyposis Drugs Market Highlights 2020 – 2030
The classic familial adenomatous polyposis (FAP) drugs market is estimated to garner a large revenue by growing at a modest CAGR over the forecast period, i.e., 2021 – 2030. The growth of the market can be attributed to factors such as the increasing prevalence of colorectal cancer in the world, a personal history of colorectal diseases or polyposis, and growing cases of inherited disorders that heighten the risk of classic FAP. Colorectal cancer is one of the most commonly occurring cancer in the world. In 2018, it was calculated that approximately 1.9 million people globally suffered from the disease. Additionally, excessive intake of tobacco, unhealthy diet and low indulgence in physical activities are considered to be the main causes of FAP. The incidences of sedentary lifestyle are witnessing a notable hike since the last decade, which in turn is expected to drive market growth in the coming years.
The market is segmented by drug type into monotherapy drugs and combination therapy drugs, out of which, the segment for monotherapy drugs is anticipated to hold the largest share in the classic familial adenomatous polyposis drugs market during the forecast period on account of their lesser number of adverse effects, reduced treatment costs, better tolerability and enhanced compliance with treatment. Moreover, on the basis of distribution channel, the hospital pharmacy segment is projected to occupy a significant market share in the near future, which can be credited to the increased interaction of prescribers and health professionals in hospitals, improved access to medical records of patients and better input in making effective prescribing decisions about drugs. CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Classic Familial Adenomatous Polyposis Drugs Market Regional Synopsis
On the basis of geographical analysis, the classic familial adenomatous polyposis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa. The market in the North America region is estimated to grab the largest market share over the forecast period on the back of high spending in the healthcare sector, growing occurrence of the disease in the United States and ongoing technological advancements to develop effective cure for colorectal disorders. It is evaluated that FAP affects more than 49, 000 families in the United States. FAP occurs in approximately 1 in every 7000 to 10000 individuals in the country. Furthermore, strong presence of major pharmaceutical companies is also evaluated to drive market growth in the region. Similarly, Europe’s market is also assessed to gather a large market share owing to the growing investments of key players for drug development in the region.
The classic familial adenomatous polyposis drugs market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the classic familial adenomatous polyposis drugs market includes the following segments:
By Treatment Type
- Minimal Invasive Colorectal Surgery
- Follow-Up Treatment
- Colonoscopy
- Upper Endoscopy
- Others
By Drug Type
- Monotherapy Drugs
- Combination Therapy Drugs
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Growth Drivers
- Growing Occurrence of Colorectal Cancer Worldwide
- Genetic istHHiHistory of Polyposis or Colorectal Disorders
Challenges
- High Treatment Cost of Classic Familial Adenomatous Polyposis
Top Featured Companies Dominating the Market
- Adhera Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cancer Prevention Pharmaceuticals, Inc.
- Haihe Biopharma Co., Ltd.
- StemSynergy Therapeutics, Inc.
- SLA Pharma AG
- DNAlite Therapeutics Inc
- GLW International
- TherapyX Inc
- Thetis Pharmaceuticals LLC
- Zikani Therapeutics Inc